Diagnostic value of immunohistochemistry for the detection of the BRAF V600E mutation in papillary thyroid carcinoma: Comparative analysis with three DNA-based assays

Thyroid

Volumn 24, Issue 5, 2014, Pages 858-866

  Ilie, Marius I ^a,b   Lassalle, Sandra ^a,b   Long Mira, Elodie ^a,b   Bonnetaud, Christelle ^b   Bordone, Olivier ^b   Lespinet, Virginie ^b   Lamy, Aude ^c   Sabourin, Jean Christophe ^c   Haudebourg, Juliette ^d   Butori, Catherine ^b   Guevara, Nicolas ^b   Peyrottes, Isabelle ^d   Sadoul, Jean Louis ^e   Bozec, Alexandre ^d   Santini, José ^d   Capper, David ^f,g   Von Deimling, Andreas ^f,g   Emile, Jean François ^h,i   Hofman, Véronique ^a,b   Hofman, Paul ^a,b  

^a UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^b PASTEUR HOSPITAL   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d CENTRE ANTOINE LACASSAGNE   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h HÔPITAL AMBROISE PARÉ   (France)

ⁱ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA; IODINE 131; BRAF PROTEIN, HUMAN; DNA; MUTANT PROTEIN;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; AUTOMATIC SLIDE STAINER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIRECT SEQUENCING; DNA DETERMINATION; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSTICS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; SNAPSHOT; THYROID CARCINOMA; THYROIDECTOMY; TISSUE MICROARRAY; ADOLESCENT; AMINO ACID SUBSTITUTION; ANTIBODY SPECIFICITY; CARCINOMA; CHEMISTRY; COMPARATIVE STUDY; GENETICS; LARGE CORE NEEDLE BIOPSY; METABOLISM; MIDDLE AGED; PATHOLOGY; THYROID GLAND; THYROID NEOPLASMS; VALIDATION STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIBODY SPECIFICITY; BIOPSY, LARGE-CORE NEEDLE; CARCINOMA; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTANT PROTEINS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY; THYROID GLAND; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84901287035     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0302     Document Type: Article

References (49)

1. Lassalle S, Hofman V, Ilie M, Butori C, Bozec A, Santini J, Vielh P, Hofman P 2010 Clinical impact of the detection of BRAF mutations in thyroid pathology: Potential usefulness as diagnostic, prognostic and theragnostic applications. Curr Med Chem 17:1839-1850.
2. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M 2012 BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: A systematic review and meta-Analysis. Medicine (Baltimore) 91:274-286.
3. Xing M 2007 BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762. (Pubitemid 350294294)
4. Xing M 2010 Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321:86-93.
5. Nikiforov YE, Nikiforova MN 2011 Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7:569-580.
6. Mehta V, Nikiforov YE, Ferris RL 2013 Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery. Head Neck 35:1499-1506.
7. Ohori NP, Singhal R, Nikiforova MN, Yip L, Schoedel KE, Coyne C, McCoy KL, Lebeau SO, Hodak SP, Carty SE, Nikiforov YE 2013 BRAF mutation detection in indeterminate thyroid cytology specimens: Underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma. Cancer Cytopathol 121:197-205.
8. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA 2011 Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 121:4700-4711.
9. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park do J 2012 The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A meta-Analysis. Cancer 118:1764-1773.
10. Asioli S, Erickson LA, Righi A, Lloyd RV 2013 Papillary thyroid carcinoma with hobnail features: Histopathologic criteria to predict aggressive behavior. Hum Pathol 44:320-328.
11. Tahmasebi FC, Farmer P, Powell SZ, Aldape KD, Fuller GN, Patel S, Hollis P, Chalif D, Eisenberg MB, Li JY 2013 Brain metastases from papillary thyroid carcinomas. Virchows Arch 462:473-480.
12. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V 2013 Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493-1501.
13. Bozec A, Ilie M, Lassalle S, Hofman V, Benaim G, Long E, Santini J, Hofman P 2013 Usefulness of ancillary methods for diagnosis, prognosis and targeted therapy in thyroid pathology. Curr Med Chem 20:639-654.
14. Rosove MH, Peddi PF, Glaspy JA 2013 BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 368:684-685.
15. Schlumberger M, French TN 2011 Targeted therapy in refractory thyroid cancer. Eur J Cancer 47:S328-S329.
16. Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D 2012 Application of a BRAF V600E mutationspecific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 36:1796-1800.
17. Blombery P, Wong SQ, Lade S, Prince HM 2012 Erdheim-Chester disease harboring the BRAF V600E mutation. J Clin Oncol 30:e331-e332.
18. Bosmuller H, Fischer A, Pham DL, Fehm T, Capper D, von Deimling A, Bonzheim I, Staebler A, Fend F 2013 Detection of the BRAF V600E mutation in serous ovarian tumors: A comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allelespecific PCR. Hum Pathol 44:329-335.
19. Bullock M, O'Neill C, Chou A, Clarkson A, Dodds T, Toon C, Sywak M, Sidhu SB, Delbridge LW, Robinson BG, Learoyd DL, Capper D, von Deimling A, Clifton-Bligh RJ, Gill AJ 2012 Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 19:779-784.
20. Capper D, Berghoff AS, Magerle M, Ilhan A, Wohrer A, Hackl M, Pichler J, Pusch S, Meyer J, Habel A, Petzelbauer P, Birner P, von Deimling A, Preusser M 2012 Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 123:223-233.
21. Feller JK, Yang S, Mahalingam M 2013 Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Mod Pathol 26:414-420.
22. Ilie M, Long E, Hofman V, Dadone B, Marquette CH, Mouroux J, Vignaud JM, Begueret H, Merlio JP, Capper D, von Deimling A, Emile JF, Hofman P 2013 Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 24:742-748.
23. Sahm F, Capper D, Preusser M, Meyer J, Stenzinger A, Lasitschka F, Berghoff AS, Habel A, Schneider M, Kulozik A, Anagnostopoulos I, Mullauer L, Mechtersheimer G, von Deimling A 2012 BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 120:e28-e34.
24. Ghossein RA, Leboeuf R, Patel KN, Rivera M, Katabi N, Carlson DL, Tallini G, Shaha A, Singh B, Tuttle RM 2007 Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: Biologic behavior and clinical implications. Thyroid 17:655-661. (Pubitemid 47311555)
25. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C,Mino-KenudsonM, LauwersGY, LodaM, Fuchs CS 2005 Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 7:413-421. (Pubitemid 41149657)
26. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, Hemminki K 2003 BRAF mutations in metastatic melanoma: A possible association with clinical outcome. Clin Cancer Res 9:3362-3368. (Pubitemid 37082731)
27. Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, Pavlick AC, Darvishian F, Christos P, Mazumdar M, Osman I, Polsky D 2012 Intra-And inter-Tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS One 7:e29336.
28. Hofman P, Butori C, Havet K, Hofman V, Selva E, Guevara N, Santini J, Van Obberghen-Schilling E 2008 Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: Comparison with epidermal growth factor receptor status. Br J Cancer 98:956-964. (Pubitemid 351341605)
29. Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, von Knebel Doeberitz M, Kloor M 2013 BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer 133:1624-1630.
30. Colomba E, Helias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, Surel S, Cote JF, Peschaud F, Capper D, Blons H, Zimmermann U, Clerici T, Saiag P, Emile JF 2013 Detection of BRAF p.V600E mutations in melanomas: Comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 15:94-100.
31. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK 2006 The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 65:364-368.
32. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A 2011 Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122:11-19.
33. Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P, Preusser M 2012 Immunohistochemical detection of the BRAF V600Emutated protein in papillary thyroid carcinoma. Am J Surg Pathol 36:844-850.
34. Zagzag J, Pollack A, Dultz L, Dhar S, Ogilvie JB, Heller KS, Deng FM, Patel KN 2013 Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery 154: 1199-1204.
35. Ghossein RA, Katabi N, Fagin JA 2013 Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. J Clin Endocrinol Metab 98:E1414-E1421.
36. Hofman V, Ilie M, Long-Mira E, Giacchero D, Butori C, Dadone B, Selva E, Tanga V, Passeron T, Poissonnet G, Emile JF, Lacour JP, Bahadoran P, Hofman P 2013 Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients. J Invest Dermatol 133:1378-1381.
37. Trovisco V, Soares P, Soares R, Magalhaes J, Sa-Couto P, Sobrinho-Simoes M 2005A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol 36:694-697. (Pubitemid 40922577)
38. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, Magalhaes J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simoes M 2005 Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446:589-595. (Pubitemid 40922263)
39. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867. (Pubitemid 38410730)
40. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA 2009 Mutational profile of advanced primary and metastatic radioactive iodinerefractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69: 4885-4893.
41. Ciarrocchi A, Cavuto S, Piana S 2013 BRAF V600E mutation and papillary thyroid cancer. JAMA 310:534.
42. Ilie M, Hofman P 2013 The potential value of immunohistochemistry as a screening tool for oncogenic targets of personalized lung cancer therapy. J Oncopathol 1:1.
43. Yip L, Nikiforova MN, Carty SE, Yim JH, Stang MT, Tublin MJ, Lebeau SO, Hodak SP, Ogilvie JB, Nikiforov YE 2009 Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 146:1215-1223.
44. Nikiforov YE, Yip L, Nikiforova MN 2013 New strategies in diagnosing cancer in thyroid nodules: Impact of molecular markers. Clin Cancer Res 19:2283-2288.
45. Alzahrani AS, Xing M 2013 Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: Potential role of BRAFV600E mutation in defining CND. Endocr Relat Cancer 20:13-22.
46. Abrosimov A, Saenko V, Rogounovitch T, Namba H, Lushnikov E, Mitsutake N, Yamashita S 2007 Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer 120:196-200. (Pubitemid 44901936)
47. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G, Vitale M 2012 The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 97:517-524.
48. Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A, Vitale M 2012A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab 97:2333-2340.
49. Marin C, Beauchet A, Capper D, Zimmermann U, Julié C, Ilie M, Saiag P, Von Deimling A, Hofman P, Emile JF 2014 Detection of BRAF p.V600E mutations on melanoma by immunohistochemistry has a good interobserver reproducibility. Arch Pathol Lab Med 138:71-75.